KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Current Assets (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Current Assets for 17 consecutive years, with $4.0 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets rose 22.31% year-over-year to $4.0 billion, compared with a TTM value of $4.0 billion through Dec 2025, up 22.31%, and an annual FY2025 reading of $4.0 billion, up 22.31% over the prior year.
  • Current Assets was $4.0 billion for Q4 2025 at Biomarin Pharmaceutical, up from $3.9 billion in the prior quarter.
  • Across five years, Current Assets topped out at $4.0 billion in Q4 2025 and bottomed at $2.3 billion in Q4 2021.
  • Average Current Assets over 5 years is $3.0 billion, with a median of $3.0 billion recorded in 2023.
  • The sharpest move saw Current Assets decreased 15.6% in 2021, then increased 26.11% in 2025.
  • Year by year, Current Assets stood at $2.3 billion in 2021, then grew by 20.98% to $2.8 billion in 2022, then rose by 7.44% to $3.0 billion in 2023, then grew by 9.35% to $3.2 billion in 2024, then increased by 22.31% to $4.0 billion in 2025.
  • Business Quant data shows Current Assets for BMRN at $4.0 billion in Q4 2025, $3.9 billion in Q3 2025, and $3.8 billion in Q2 2025.